The Complete Nootropics Masterclass Volume 3 (7/11) — Nicotinics, Muscarinics & Racetams

[enchanted_elixir]

THE COMPLETE NOOTROPICS MASTERCLASS
VOLUME 3: THE LIST OF COMPOUNDS
PART 7 OF 11 | NICOTINIC, MUSCARINIC & RACETAM COGNITIVE MODULATION​

---

23.4 Nicotinic-Receptor Compounds​

Nicotinic receptors are fast ion channels named for their response to nicotine. Activating them can briefly sharpen cue detection and task entry, but the receptors desensitize, and repeated nicotine exposure can convert an apparent cognitive aid into relief from withdrawal that the drug itself created. Tropisetron approaches the system differently through alpha7 modulation while also blocking 5-HT3 receptors.

Spoiler: 23.4.1 Nicotine — Fast, Effective Attention With a Reinforcement Bill Attached

23.4.1 Nicotine — Fast, Effective Attention With a Reinforcement Bill Attached

What it is: Nicotine (C10H14N2) is a plant alkaloid and agonist at neuronal nicotinic acetylcholine receptors. Tobacco smoke causes enormous harm through combustion products, but purified nicotine is still an addictive psychoactive drug with cardiovascular, developmental and dependence risks. Gum, lozenges and patches are regulated smoking-cessation medicines—not evidence that initiating nicotine in a nonuser is a good enhancement trade.

What it may feel like: In a nicotine-naïve responder, a low or slowly delivered exposure can make the visual field feel “locked,” boring reading feel immediately actionable, and distractibility collapse into a calm, narrow channel. It can also cause a head rush, nausea, hiccups, cold hands, racing heart, anxiety or dizziness. With repetition, the state changes: the dose increasingly feels like relief from the irritability, fog and craving created by the previous dose. Focus begins migrating from the work toward obtaining and timing nicotine.

The simplest description: Nicotine presses the brain’s attention and reinforcement buttons at the same time. The first button can improve vigilance and working memory; the second teaches the brain that pressing it again matters. That learning mechanism is the reason an effective acute nootropic can become a net cognitive tax.

How It Works

Nicotine activates nicotinic acetylcholine receptors, including α4β2, α7 and other subtypes, causing ion flow and release/modulation of dopamine, norepinephrine, acetylcholine, glutamate and GABA. Rapid receptor activation is followed by desensitization and, with repeated exposure, receptor and behavioral adaptation. It crosses the blood-brain barrier quickly; rate of delivery strongly affects reinforcement, which is why inhaled nicotine is more addictive than a slow patch.

Central attention/reward effects coexist with peripheral sympathetic and autonomic effects: higher heart rate and blood pressure, vasoconstriction, altered GI activity and nausea. Nicotine is not the main carcinogen in cigarettes, but “not smoke” does not mean metabolically or developmentally harmless.

Dose and How It Is Used

Regulated nicotine replacement is dosed for people already dependent on tobacco, commonly as 2- or 4-mg gum/lozenges or patches releasing 7–21 mg over a day. A 2-mg gum does not deliver 2 mg to blood; systemic delivery is roughly around 1 mg and varies with technique. Those labels are cessation protocols, not recommendations for a nicotine-naïve student. No initiation dose is supplied.

Gum and lozenges are designed for buccal absorption. Gum uses “chew and park”; swallowing nicotine-rich saliva increases nausea and loses more drug to first-pass metabolism. Acidic drinks—including coffee, soda and juice—reduce buccal absorption, so cessation labels advise avoiding food/drink shortly before and during use. Patches produce slow, steady exposure and should never be cut unless that specific product explicitly allows it. Smoking/vaping produces the fastest brain spike and the worst reinforcement trade, alongside product-specific toxicants.

Solubility and practical administration: Nicotine free base is a water-miscible, volatile liquid, while pharmaceutical salts and delivery matrices alter pH, absorption, and speed. This chemistry does not justify swallowing or diluting concentrated nicotine liquid, which can be fatal in small dosing errors; use only a regulated route-specific product exactly as labeled, and keep it away from skin, children, and pets.

Timing and Pharmacokinetics

• Subjective onset: Inhaled nicotine reaches the brain within seconds; gum/lozenge is usually felt over 10–30 minutes; patches rise over hours.
• Pharmacologic onset: Route-dependent and tightly linked to delivery speed.
• Tmax: Gum is typically about 30–60 minutes (some FDA studies around one hour); lozenges around one hour; patches roughly 2–10 hours depending on product.
• Absorption/bioavailability: Buccal and transdermal routes bypass much first-pass metabolism. Swallowed oral nicotine has low bioavailability, generally below 20%; delivered systemic amount is less than the labeled gum/lozenge content.
• Full practical effect: Acute attention and autonomic effects occur on the first exposure; dependence/tolerance can develop across repeated days and weeks.
• Subjective duration: Gum/lozenge effects often last one to three hours; patches maintain exposure for 16–24 hours.
• Half-life: Nicotine averages about 2 hours; cotinine averages roughly 16–20 hours.
• Accumulation/steady state: Repeated dosing through the day accumulates; daily use produces receptor adaptation and background cotinine. Patches approach a controlled plateau but still sustain dependence.
• Near-complete elimination/washout: Parent nicotine is mostly gone after roughly 10 hours, but cotinine, receptor adaptation, craving and withdrawal persist far longer.
• Metabolism/elimination: CYP2A6 converts most nicotine to cotinine; additional oxidation and glucuronidation products are excreted mainly in urine. Genetics, sex hormones, pregnancy, liver/kidney function and interacting drugs change clearance.

Nicotine pharmacokinetics and metabolism · Route-specific population PK · FDA nicotine-gum PK review

Evidence and Experiences

Controlled studies show that nicotine can improve attention, vigilance and some working-memory measures, especially in abstinent smokers and selected low-baseline performers. A smoker moving from withdrawal to normal is not evidence of supernormal enhancement. Effects in never-users are smaller and inconsistent across tasks, while addiction, tolerance and adverse effects are not captured by a one-session cognitive score.

Forum reports illustrate the trap perfectly. Early users describe calm laser focus, rapid completion of dull work and unusually good performance after little sleep. Longer-term replies describe tolerance within days, gum dependence, rebound scrolling and the realization that attention has shifted toward the next dose. Some nicotine-naïve users feel only nausea or anxiety. One impressive test score is an anecdote with no counterfactual; the reliable population-level property is reinforcement. Early productivity followed by dependence warnings · Calm focus and mixed response · Rebound distraction and addiction discussion

Safety, Interactions, and Monitoring

Acute adverse effects include nausea, vomiting, hiccups, mouth irritation, dizziness, headache, anxiety, tremor, sweating, palpitations and increased heart rate/blood pressure. Toxicity can cause severe vomiting, confusion, weakness, abnormal heart rhythm, seizures, respiratory failure and death. Liquid nicotine is a poisoning hazard to children and pets. Seek emergency help for severe symptoms or accidental ingestion.

Avoid nicotine initiation in pregnancy, breastfeeding and adolescence because developing brains and fetuses are especially vulnerable. Cardiovascular disease, uncontrolled hypertension, arrhythmia, recent cardiac events, seizure vulnerability and strong addiction history require medical context. Stimulants and caffeine can amplify cardiovascular/anxiety effects; acidifying oral drinks reduce buccal delivery; CYP2A6 variability changes exposure. Smoking cessation treatment should follow clinical guidance rather than this enhancement profile.

Tolerance and dependence are central, not optional footnotes. Cycling schemes from forums do not reliably prevent conditioned use, and a person who starts negotiating exceptions is already receiving information about reinforcement. Track every use, craving, dose escalation, pulse/blood pressure, sleep, nausea, gum/mouth health, objective output and off-days. Regulated NRT has far better content control than pouches, vaping liquids or research nicotine; keep all products childproof.

Bottom Line

Nicotine really can make a dull task feel sharply relevant. That acute effectiveness is exactly why it is dangerous as a casual nootropic: the brain learns the tool faster than the user plans. For a current smoker, regulated NRT is harm reduction; for a nicotine-naïve student, creating a dependence loop for a temporary attention gain is usually a poor bargain.

Spoiler: 23.4.2 Tropisetron — Smooth α7-Nicotinic Modulation With Constipation as the Reality Check

23.4.2 Tropisetron — Smooth α7-Nicotinic Modulation With Constipation as the Reality Check

What it is: Tropisetron (C17H20N2O2, generally used as the hydrochloride) is a prescription 5-HT3 serotonin-receptor antagonist developed as an antiemetic. It also acts at α7 nicotinic acetylcholine receptors and has been studied for sensory gating and cognition in schizophrenia. It is not approved as a healthy-person nootropic, and availability varies by country.

What it may feel like: Positive reports describe a quiet sharpening of perspective: vision and thought feel slightly cleaner, distraction has less emotional pull, and focus improves without stimulant urgency. The effect is usually subtle. The signature failure is gastrointestinal—bowel motility can slow enough that the user feels physically “stuck”—along with headache, fatigue, dizziness or no cognitive change. Heavy nicotine exposure may blunt the subjective difference, but that is anecdotal.

The simplest description: Tropisetron blocks one serotonin channel involved in nausea and gut signaling while partially engaging an α7 nicotinic receptor involved in attention and sensory filtering. The hoped-for result is cleaner gating—less irrelevant noise entering awareness. The gut reminds the reader that this is a systemic antiemetic, not a brain-selective focus molecule.

How It Works

Tropisetron is a high-affinity competitive 5-HT3 antagonist and a partial agonist/modulator at α7 nicotinic receptors. Human PET work supports dose-dependent brain α7-receptor occupancy, and schizophrenia trials link treatment to improved P50 auditory gating and selected cognitive measures. It does not behave like nicotine at every nicotinic subtype and does not directly flood the brain with acetylcholine.

Central α7 activity is the cognitive hypothesis; peripheral 5-HT3 blockade contributes to antiemetic action and reduced intestinal propulsion/constipation. It crosses the blood-brain barrier, but response varies dramatically with CYP2D6 metabolism and baseline nicotine/cholinergic state.

Dose and How It Was Studied

The traditional antiemetic oral dose is commonly 5 mg, while small schizophrenia trials studied 5, 10 and 20 mg/day or 10 mg/day for several weeks in nonsmoking patients stabilized on antipsychotics. Two participants in the 20-mg group of one short trial withdrew because of adverse effects. These are clinical exposures, not a healthy-student titration schedule, and no personal dose is supplied.

The prescription hydrochloride capsule is an oral pharmaceutical formulation; it is not interchangeable with an unverified free-base research solution. It may be taken according to the local product label, often before chemotherapy in the antiemetic context. Food, fasting, sublingual use and home solvent strategies have not been shown to improve cognitive selectivity. Because constipation is dose-limiting for some users, adding laxative stacks to force continuation can hide an unfavorable response.

Solubility and practical administration: Pharmaceutical tropisetron is commonly supplied as the water-soluble hydrochloride salt. Oral capsules or tablets do not require dietary fat, but a salt dissolving in water does not validate improvised solutions or research powder; follow the exact regulated formulation and its food instructions.
Timing and Pharmacokinetics

• Subjective onset: Usually described within one to three hours when noticeable.
• Pharmacologic onset: 5-HT3 blockade and CNS occupancy occur after first-dose absorption.
• Tmax: Approximately 2.6 hours after a 5-mg oral capsule in healthy volunteers.
• Absorption/bioavailability: Absorption is substantial, but first-pass metabolism makes mean absolute bioavailability about 60%, with a very wide observed range (27–99%).
• Full practical effect: Antiemetic and subtle cognitive effects can occur on day one; schizophrenia outcomes were also assessed over 10 days to eight weeks.
• Subjective duration: Commonly most of a day; poor metabolizers may experience longer effects.
• Half-life: Approximately 6–8 hours in extensive CYP2D6 metabolizers and 30–40 hours in CYP2D6-deficient poor metabolizers.
• Accumulation/steady state: Little daily accumulation is expected in rapid/normal metabolizers compared with potentially substantial accumulation over a week in poor metabolizers.
• Near-complete elimination/washout: Roughly 1.5–2 days for a six-to-eight-hour half-life versus 6–8 days for a 30–40-hour half-life; genotype makes one universal washout false.
• Metabolism/elimination: Hepatic oxidation is dominated by CYP2D6 with contributions from other CYP pathways; metabolites and some parent are eliminated through urine and feces.

Healthy-volunteer oral PK · Healthy-human α7 PET occupancy · Short schizophrenia dose-ranging trial

Evidence and Experiences

Small randomized trials in nonsmoking patients with schizophrenia reported improved P50 gating and selected cognitive scores over one day to several weeks. That is a biologically coherent clinical signal, but sample sizes were small, participants were impaired and on antipsychotic treatment, and it does not establish enhancement in healthy adults. There is no large healthy-student cognition program.

Forum reports are limited but increasingly consistent about texture: subtle smooth clarity, slightly sharper visual/cognitive framing, or no dramatic effect. Constipation and visibly slowed gut motility dominate negative accounts and can outweigh the cognitive benefit even at lower exposure. One older self-test was too confounded by test habituation and a prescription/modafinil stack to quantify benefit. Self-test with important confounding · Recent smooth-effect and constipation reports

Safety, Interactions, and Monitoring

Common adverse effects include constipation, headache, dizziness, fatigue and abdominal discomfort. Serious concerns include severe constipation/ileus, allergic reaction, syncope or rhythm disturbance in susceptible people, and prolonged exposure in CYP2D6 poor metabolizers. Stop for inability to pass stool/gas with pain or vomiting, fainting, severe palpitations, allergic swelling/wheezing, confusion or significant neurologic change.

Other 5-HT3 antagonists, QT-affecting drugs, CYP2D6 inhibitors, anticholinergic/constipating medicines, opioids and slowed-gut medications can compound risk. Nicotine and other α7/nicotinic agents make the central response harder to predict. Bowel obstruction, severe constipation, significant conduction/QT risk, liver disease, pregnancy/breastfeeding and use in minors require clinical guidance.

Dependence is not expected; receptor tolerance and a cognitive cycling rule are not established. Track bowel frequency and ease, abdominal symptoms, exact dose/formulation, pulse/blood pressure, dizziness, sleep, nicotine use and an objective cognition measure. Product quality should favor regulated prescription capsules where legally used; research products require independent identity, salt form, assay, impurities and residual-solvent testing.

Bottom Line

Tropisetron may feel like turning down irrelevant background noise rather than turning up motivation. Its human α7 occupancy and schizophrenia data make it more credible than many niche cholinergics, but healthy enhancement remains unproven. Constipation is not a cosmetic side effect—it is often the clearest sign that the systemic cost exceeds the subtle cognitive return.

23.5 Muscarinic-Receptor Compounds​

Muscarinic receptors are slower G-protein-coupled receptors that shape network state rather than producing one rapid electrical pulse. M1 is the principal cognitive target because it is abundant in cortex and hippocampus, while less selective muscarinic stimulation also reaches the heart, gut, glands, eyes and other peripheral organs.

23.6 Why M1 Is the Principal Muscarinic Cognitive Target​

M1 receptors are abundant in cortex and hippocampus and help couple acetylcholine to attention, working memory and plasticity. Global muscarinic activation also reaches M2–M5 receptors and peripheral organs, producing heart-rate, gastrointestinal, sweating, visual and motor effects. A successful M1 strategy should amplify cognition-relevant signaling without turning the entire body cholinergic.

AF710B—now called ANAVEX3-71—is placed separately below because it is not a choline donor or acetylcholinesterase inhibitor. It is an investigational receptor-directed strategy whose human efficacy remains unproven.

Spoiler: 23.6.1 AF710B / ANAVEX3-71 — M1 and Sigma-1 Signaling With Real Human PK

23.6.1 AF710B / ANAVEX3-71 — M1 and Sigma-1 Signaling With Real Human PK

What it is: AF710B, now developed as ANAVEX3-71, is an investigational small molecule (C20H27N3OS) combining positive allosteric/agonistic activity at the M1 muscarinic acetylcholine receptor with sigma-1-receptor agonism. It has completed healthy-volunteer Phase I work and a 71-participant Phase II schizophrenia study, but it is not approved for cognition, schizophrenia or Alzheimer disease.

What it may feel like: The plausible positive experience is not stimulation. Users describe becoming more present and patient, holding several ideas without losing one, noticing that new information “sticks” when they later retrieve it, or watching thoughts organize themselves with less emotional noise. Other reports describe mild headache, tiredness, word-finding difficulty, vivid dreams, heavy eyes after sleep, transient blood-pressure sensations, marginal or no benefit. Most reports use unverified research material and some later add TAK-653 or other compounds, destroying attribution.

The simplest description: M1 receptors help the cortex mark and hold relevant information; sigma-1 receptors act more like stress-sensitive cellular organizers at the endoplasmic reticulum–mitochondria interface. ANAVEX3-71 is designed to support both the immediate information signal and the cell environment processing it. That attractive model is still a hypothesis for healthy enhancement, not permission to treat forum powder as the clinical drug.

How It Works

ANAVEX3-71 is described as an M1 muscarinic positive allosteric modulator with agonistic effects and a sigma-1-receptor agonist. M1 signaling can influence cortical attention, working memory and plasticity without directly stimulating the peripheral M2 cardiac receptor as a nonselective muscarinic agonist would. Sigma-1 signaling modulates calcium handling, protein stress, mitochondria and receptor networks. Preclinical Alzheimer models report cognitive and pathology changes, but animal disease modification does not prove human regeneration.

Human EEG/ERP changes in schizophrenia and Phase I CNS development support brain engagement. The molecule is orally active and rapidly absorbed. Its exact balance between central M1 benefit, sigma-1 activity and peripheral off-target effects at any research-chemical exposure is not known.

Dose and How It Was Studied

The Phase I single-ascending-dose program studied 5–200 mg orally in healthy adults. The 2025 Phase II schizophrenia program used 30 and 60 mg in the multiple-dose part and 60 mg versus placebo in the longer randomized part, on top of stable antipsychotic medication. Those are monitored clinical exposures and not an author-supplied healthy-person dose. Online oral or intranasal ranges are uncontrolled anecdotes; intranasal use adds tissue injury and does not reproduce the capsule PK.

The research free base is poorly characterized for consumer water and pH solubility; laboratory suppliers dissolve it in DMSO, which is not a home human formulation. Clinical trials used standardized oral capsules, and a modified-release tablet has since been developed. Food did not materially affect Phase I immediate-release PK, so fasting has no demonstrated exposure advantage. A cloudy water mixture or “bacteriostatic water” suspension does not prove content uniformity, stability or absorption.

Timing and Pharmacokinetics

• Subjective onset: Reports range from several hours to a subtle difference noticed after several days; nonresponse is common.
• Pharmacologic onset: Immediate-release oral drug is rapidly absorbed and can engage CNS biomarkers during clinical dosing.
• Tmax: Median about 1 hour for the immediate-release capsule; the newer modified-release prototype delayed peak to about 5.5 hours. The active M8 metabolite peaks later, around 1.5 hours after immediate release.
• Absorption/bioavailability: It is orally absorbed with linear, dose-proportional exposure from 5–200 mg, but absolute oral bioavailability has not been publicly established.
• Full practical effect: Acute M1/sigma-1 signaling begins on the first dose; clinical schizophrenia biomarkers and safety were assessed across repeated days/weeks, while healthy memory benefit has not been established.
• Subjective duration: Often described as a working-day background change; dreams or sleep quality may reveal effects later.
• Half-life: Mean apparent terminal half-life is approximately 3.56 hours for parent and 6.59 hours for M8; individual parent estimates were variable.
• Accumulation/steady state: The short parent half-life predicts limited parent accumulation with once-daily immediate release; M8 can persist longer. Multiple-dose and modified-release formulations should not be inferred from forum powder.
• Near-complete elimination/washout: Roughly 18 hours for five mean parent half-lives and about 33 hours for M8, but this is a PK estimate rather than an interaction washout.
• Metabolism/elimination: Parent converts rapidly to M8 and other metabolites; detailed consumer-relevant enzyme and excretion fractions are not yet fully public. Food did not alter parent or M8 PK in the Phase I analysis.

Peer-reviewed human PK and food-effect study · Human concentration–QTc study · Phase II schizophrenia record

Evidence and Experiences

This compound has real human development: Phase I found linear PK and no clinically relevant ECG-interval effect across single 5–200-mg exposures. In October 2025 the sponsor reported that its small Phase II schizophrenia study met the primary safety/tolerability endpoint and showed encouraging EEG/ERP and biomarker trends. It did not establish broad clinical efficacy, and company-reported exploratory trends are weaker than a replicated peer-reviewed cognitive outcome. Healthy-person memory enhancement remains untested.

The online phenomenology is newly emerging. The most credible positive description is “things stick faster, and I notice only when I retrieve them,” plus longer working-memory hold and calmer metacognition. Null and negative accounts include no measurable change after weeks, marginal recall, slowed thought, word-finding difficulty, headache and vivid dreams with tired waking. A recent journal became confounded after TAK-653 was added, and commercial identity remained unverified. Recent AF710B journal · Calm organization and mixed reports · Subtle or absent change in a multi-compound stack · Sponsor’s 2025 Phase II topline report

Safety, Interactions, and Monitoring

Early controlled safety is reassuring but small. Possible effects include headache, fatigue, dizziness, vivid dreams/sleep disruption, cognitive slowing and muscarinic GI/autonomic symptoms. Long-term healthy-adult, reproductive, developmental and rare-event risks remain unknown. Stop for severe headache, fainting, marked blood-pressure or heart-rate change, confusion, hallucinations/mania, seizure, persistent neurologic change, suicidal deterioration or allergic reaction.

Interactions are inadequately mapped. Other muscarinic agonists, acetylcholinesterase inhibitors, large choline loads, nicotine/nicotinic compounds, sigma-1 ligands, antipsychotics and complex glutamatergic stacks can alter response. Do not infer safety from the Phase II study unless the same formulation, dose, screening, stable-medication context and monitoring are present. Pregnancy/breastfeeding, adolescence, seizure disorders, bipolar/psychotic instability, cardiovascular disease and major liver/kidney disease lack a self-use basis.

Tolerance, dependence, withdrawal and a healthy enhancement cycle are not established. The parent’s short half-life does not guarantee that downstream signaling or M8 has ended. Track verified product, formulation, dose and clock time, pulse/blood pressure, sleep/dreams, headache, mood, word retrieval, working-memory and delayed-recall tasks, and function after stopping. Research material requires independent identity, assay, impurities, residual-solvent, stability and—where relevant—salt/formulation testing.

Bottom Line

AF710B/ANAVEX3-71 is no longer just an animal M1 story: it has human PK, a known short parent half-life, a measurable metabolite and early clinical safety data. The useful subjective image is calmer organization and information that becomes easier to hold or retrieve, not stimulation. But the clinical evidence is still about investigational treatment and biomarkers, while healthy enhancement and vendor-product equivalence remain unknown.

23.7 Cholinergic Monitoring​

Track the exact compound, clock time, headache location, nausea, bowel activity, salivation, sweating, muscle tension, resting pulse, dream intensity, sleep continuity, attention and memory accuracy. A vivid dream or a feeling of mental pressure is not proof that learning improved.

Chapter 24 — Racetams​

Racetams are a chemically related but pharmacologically diverse family built around a pyrrolidone-like scaffold. The name creates the illusion that every member performs the same action at a different potency. It does not. Some were developed as proposed cognitive enhancers, some as neuroprotective, psychiatric, or pain candidates, and another branch became successful antiseizure medicine through synaptic-vesicle protein 2A (SV2A). A family resemblance in chemistry is not a shared guarantee of memory enhancement.

24.1 A Brief History of Racetams​

Piracetam was synthesized at UCB in 1964 during an attempt to create GABA-related compounds that might promote sleep. It did not behave like GABA and did not fit the familiar categories of stimulant, sedative, or tranquilizer. Corneliu Giurgea instead reported unusual learning- and memory-related effects in experimental systems and used piracetam to define the term nootropic. The original ideal—support learning and cortical function while remaining unusually safe—was built around this unexpected molecule.

The descendants then separated into different branches. Aniracetam, oxiracetam, pramiracetam, phenylpiracetam, and others changed solubility, kinetics, stereochemistry, or functional profile. Levetiracetam later showed that a racetam scaffold could become a clinically useful antiseizure drug through SV2A rather than a general cognitive enhancer; brivaracetam and seletracetam were optimized along that branch. The history is not a ladder from weak to strong nootropic. It is a chemical family repeatedly repurposed toward different biological targets.

24.2 What the Cognition-Oriented Racetams Are Proposed to Do​

The cognition-oriented racetams are discussed as modulators of glutamatergic transmission, membrane dynamics, cholinergic demand, mitochondrial function, or plasticity. The balance differs by molecule, and many mechanisms remain proposed rather than proven at ordinary human exposures. Think of them less as pouring gasoline onto the brain and more as changing how strongly an active circuit registers or recovers a signal. If the relevant circuit is learning something useful, that could theoretically support encoding. If the brain is sleep-deprived, anxious, or rehearsing noise, greater signal gain does not automatically create intelligence.

The recurring reports—easier recall, verbal continuity, sensory clarity, stamina, stimulation, emotional flattening, insomnia, or headache—are clues, not proof. Expectations, withdrawal, concurrent choline, task choice, sleep, and product identity can all create a different experience. Feeling unusually “on” is not the same endpoint as remembering more accurately a week later.

24.3 Evidence, Choline Interactions, Tolerance, and Cycling​

Human evidence is uneven and often concentrated in cognitive impairment, stroke, dementia, epilepsy, pain, or small older trials rather than healthy high-performing adults. Piracetam's longevity and relatively low acute toxicity do not prove a large enhancement effect, and a stronger effect by mass does not prove a better effect. Gray-market label inaccuracies further make failure, benefit, and adverse reactions difficult to attribute.

Racetam headaches are often treated as proof that acetylcholine was depleted and more choline is mandatory. That explanation is possible in some contexts but not established as a universal rule. Headache can also reflect dose, sleep loss, tension, dehydration, stimulation, impurities, or excessive cholinergic signaling; adding choline helps some users and makes others feel depressed, rigid, nauseated, or worse. Tolerance is especially prominent in reports about phenylpiracetam, while most cycling rules come from anecdotes rather than controlled evidence. Each compound needs its own kinetics, adaptation, and risk analysis.

24.4 Cognition-Oriented and Experimental Racetams​

Spoiler: 24.4.1 Piracetam — The Original Racetam: Subtle, Inconsistent, and Better Studied Than Most

24.4.1 Piracetam — The Original Racetam: Subtle, Inconsistent, and Better Studied Than Most

What it is: Piracetam is 2-oxo-1-pyrrolidine acetamide, the original racetam and the compound for which Corneliu Giurgea coined nootropic. It resembles a cyclic GABA derivative chemically but does not behave like a GABA sedative.

What it may feel like: A responder may not feel “drugged.” Instead, conversation can run with fewer word-search pauses, associations arrive a little faster, music or colors seem richer, and several hours of reading feel less abrasive. Many people notice nothing. Others report pressure headaches, fog, irritability, insomnia, emotional flattening, or the strange experience of feeling sharper while objective work does not improve.

The simplest description: Piracetam is more like reducing friction in an already-running mental machine than pressing an accelerator. If you are not learning, speaking, or solving anything, there may be almost nothing obvious to feel.

How It Works

Piracetam has no single accepted receptor target. Proposed actions include changing neuronal-membrane fluidity and modulating ion channels, AMPA/NMDA-related glutamate signaling, and cholinergic function. Its effects appear activity-dependent: it may alter how strongly active networks communicate, but it cannot decide whether the network is practicing mathematics, rehearsing anxiety, or operating on four hours of sleep.

It reaches cerebrospinal fluid and brain tissue but is not selectively confined to cognition. The drug is highly polar, binds little to plasma protein, undergoes essentially no metabolism, and is cleared mainly unchanged by the kidneys.

Dose and How It Was Studied

Clinical trials and licensed indications have used gram-level daily doses, often divided; an 800 mg single dose has modern human pharmacokinetic data. Those medical and research exposures are not a healthy-student recommendation, and taking more because the first dose felt subtle is particularly poor reasoning.

Piracetam is highly water soluble and can be swallowed with water. Food is not required for absorption: it may lower and delay the peak without materially reducing total exposure, so eating is mainly a comfort and timing choice. Kidney function matters far more than fasting.

Timing and Pharmacokinetics

• Subjective onset: Commonly described as one to three hours, although some users report only a days-long background change or no effect.
• Pharmacologic onset / Tmax: Plasma peaks are usually reached in roughly 0.5–2.5 hours, depending on food and formulation.
• Absorption/bioavailability: Oral absorption is rapid and close to complete.
• Full practical effect: Acute changes, if real, should be judged during an actual verbal or learning task; clinical studies usually assess repeated use over weeks.
• Subjective duration: Often described as several hours to most of a work period.
• Half-life: About 4–5 hours in healthy adults; renal impairment can prolong it substantially.
• Accumulation/steady state: With regular dosing, approximate steady state should occur within about a day, but impaired renal clearance changes this.
• Near-complete elimination: Roughly one day after a single dose in healthy renal function using the five-half-life rule; longer with kidney impairment.
• Metabolism/elimination: Minimal metabolism; predominantly renal excretion of unchanged piracetam.

Human 800 mg pharmacokinetics · Food-effect and bioequivalence study

Evidence and Experiences

Piracetam has decades of human research, but much of it concerns dementia, stroke, vertigo, myoclonus, dyslexia, or other impaired populations. Reviews do not establish a reliable IQ or broad cognitive-enhancement effect in healthy young adults. Old age, impairment, and clinical endpoints cannot be quietly converted into promises for a healthy student.

Forum reports cluster around smoother verbal flow, associative recall, richer sensory detail, and mental stamina, but nonresponse is extremely common. Headache is often blamed on “choline depletion,” yet dehydration, tension, sleep loss, dose, impurities, or too much cholinergic activity are also plausible; automatically adding choline can produce low mood, nausea, rigidity, or more fog. Verbal-fluency discussion

Safety, Interactions, and Monitoring

Reported adverse effects include headache, nausea, diarrhea, dizziness, agitation, sleep disruption, fatigue, and mood or cognitive worsening. Seek help for seizure, mania, suicidality, severe rash, fainting, chest symptoms, abnormal bleeding, or persistent neurologic change.

Use particular caution with anticoagulants/antiplatelets, seizure treatment, cholinesterase inhibitors, nicotine, large choline doses, stimulants, and complex psychiatric regimens. Kidney disease, bleeding disorders, pregnancy/breastfeeding, minors, bipolar disorder, and psychosis require medical review. Dependence is not expected; tolerance and cycling rules are not established. Product-quality testing should verify identity, assay, microbes, heavy metals, residual solvents, and batch consistency; track sleep, mood, headache, delayed recall, task errors, and next-day function.

Bottom Line

Piracetam is the historical baseline racetam: real pharmacology and unusually clear human kinetics, but uncertain healthy-person benefit. If it works, expect reduced cognitive friction rather than motivation or a stimulant rush—and judge it by work completed and remembered, not by how “smart” it feels.

Spoiler: 24.4.2 Aniracetam — Short-Lived Parent Drug, Metabolite-Driven Effects, and a Socially “Looser” Reputation

24.4.2 Aniracetam — Short-Lived Parent Drug, Metabolite-Driven Effects, and a Socially “Looser” Reputation

What it is: Aniracetam is 1-(4-methoxybenzoyl)-2-pyrrolidinone (Ro 13-5057), a more lipophilic racetam that is rapidly converted into several metabolites. The parent molecule disappears quickly, so aniracetam’s lived profile cannot be read from the parent half-life alone.

What it may feel like: Positive reports describe background social anxiety turning down: words are available, conversation feels less overanalyzed, music becomes more emotionally textured, and work feels calm rather than forced. Negative reports describe bodily anxiety, sedation, irritability, vivid dreams, headache, low motivation, or no effect. It is neither a dependable anxiolytic nor a miniature benzodiazepine.

The simplest description: Aniracetam is often described as taking the social and emotional handbrake off without creating a stimulant launch—but this is an anecdotal pattern, not a controlled healthy-adult guarantee.

How It Works

Aniracetam and its metabolites modulate AMPA-type glutamate receptors and may influence metabotropic glutamate, cholinergic, serotonergic, and dopaminergic signaling. “AMPA modulation” means changing the response to glutamate already released during active signaling; it does not manufacture useful thoughts or repair sleep deprivation.

The parent compound is lipophilic and enters the CNS, but extensive first-pass metabolism produces N-anisoyl-GABA, 2-pyrrolidinone, and related metabolites that can contribute longer than parent aniracetam remains measurable. Central effects coexist with gastrointestinal and sleep effects.

Dose and How It Was Studied

A 400 mg single oral dose has human pharmacokinetic data, while older clinical regimens commonly totaled roughly 1–1.5 g/day in divided doses. These are study and medical-use facts, not a dosing instruction for healthy enhancement.

Aniracetam is poorly water soluble. A verified manufactured oral product is generally taken with a meal—often one containing some fat—for practical dispersion and stomach comfort, although “fat soluble” does not mean an oily improvised mixture has validated absorption. Fasting is not proven superior, and sublingual research powder has no established advantage.

Timing and Pharmacokinetics

• Subjective onset: Reports commonly place it around 20–60 minutes.
• Pharmacologic onset / Tmax: Parent aniracetam peaked at about 0.4 hours in a fasting human study.
• Absorption/bioavailability: It is orally absorbed but undergoes extensive first-pass metabolism; intact-parent exposure is low.
• Full practical effect: Often described during the first one to three hours, while metabolite effects may be broader and less obvious.
• Subjective duration: Commonly reported as two to five hours, with substantial disagreement.
• Half-life: Parent drug is roughly 0.5 hour; this is not the half-life of the entire active-metabolite experience.
• Accumulation/steady state: Parent accumulation should be limited, but repeated exposure to metabolites and downstream adaptation are insufficiently characterized.
• Near-complete elimination: Parent drug clears within a few hours; an honest whole-effect washout cannot be calculated without complete metabolite kinetics.
• Metabolism/elimination: Extensive hepatic/first-pass conversion followed by renal elimination of metabolites.

Human pharmacokinetics review record

Evidence and Experiences

Human evidence is older and concentrated in cognitive impairment rather than healthy high performers. The mechanistic literature is interesting, but it does not establish treatment of social anxiety or reliable enhancement in healthy adults.

Forum experiences are unusually polarized. Some users describe easier speech, bonding, recall, and a return of their “old social self”; others report fatigue, bodily anxiety, irritability, vivid dreams, or complete nonresponse. Activity matters: the alleged social effect becomes visible in conversation, not while waiting for a buzz. Longer-term social-anxiety account · Anxiety and sedation account

Safety, Interactions, and Monitoring

Headache, nausea, diarrhea, dizziness, sedation, agitation, insomnia, vivid dreams, low mood, and cognitive worsening are reported. Stop for mania, suicidality, hallucinations, seizure, severe rash, fainting, chest symptoms, or prolonged insomnia.

Use caution with other AMPA/glutamate-active compounds, cholinergics, stimulants, sedatives, anticoagulants, and psychiatric medication. Pregnancy/breastfeeding, minors, bipolar disorder, psychosis, seizure history, and serious liver/kidney disease lack a safe self-experiment basis. Dependence is not established; tolerance reports conflict, and no evidence-based cycle exists. Product testing should confirm identity, assay, impurities, residual solvents, and microbes. Track conversation quality, task accuracy, sleep, mood, headache, and next-day function.

Bottom Line

Aniracetam’s practical identity is a brief, sometimes calming racetam whose metabolites matter more than its 30-minute parent half-life suggests. The socially fluid experience is relatable but anecdotal; equal weight belongs to sedation, anxiety, and nonresponse.

Spoiler: 24.4.3 Oxiracetam — A Cleaner, More Task-Locked Racetam With Mixed Stimulation

24.4.3 Oxiracetam — A Cleaner, More Task-Locked Racetam With Mixed Stimulation

What it is: Oxiracetam is 4-hydroxy-2-oxo-1-pyrrolidine acetamide, sometimes called hydroxypiracetam. It is a water-soluble racetam with more human pharmacokinetic information than most experimental members of the family.

What it may feel like: On a good response, mathematics, coding, or lecture work can feel more linear: fewer irrelevant branches, cleaner recall, and enough mild activation to remain engaged without an amphetamine-like push. Other users become relaxed or sleepy, irritable, foggy, or “slightly drunk”; many notice nothing until they compare actual work. It is not a rescue drug for sleep deprivation.

The simplest description: Oxiracetam is commonly experienced as making an active thinking process cleaner, not making you want to begin it.

How It Works

Its exact human cognitive mechanism is unresolved. Preclinical work suggests modulation of AMPA/NMDA-related glutamatergic signaling, cholinergic activity, membrane processes, and energy-related signaling. Activity-dependent modulation means a demanding task supplies the traffic; oxiracetam may change how efficiently that traffic moves, but an empty road still looks empty.

Oxiracetam is polar, enters the brain only to a limited degree relative to plasma, and is eliminated substantially through the kidneys. Central effects can therefore coexist with renal accumulation and peripheral adverse effects.

Dose and How It Was Studied

Human pharmacokinetic studies have examined single oral exposures from approximately 400 mg to 3,200 mg, and older trials used repeated dosing. Those research exposures do not define a healthy-user dose, especially because benefit in impaired populations does not establish enhancement in a rested student.

It is water soluble and can be taken in a verified oral formulation with water. Food is optional for stomach comfort rather than required for absorption; fasting may produce a faster peak but is not automatically better. Renal function is a major determinant of clearance.

Timing and Pharmacokinetics

• Subjective onset: Commonly reported around 30–90 minutes, if noticed at all.
• Pharmacologic onset / Tmax: Human studies place Tmax at roughly one to three hours; one Phase I study found about one hour fasting.
• Absorption/bioavailability: Estimated oral bioavailability is roughly 56–82% across studies.
• Full practical effect: Best judged during the first several hours of real learning or analytical work.
• Subjective duration: Forum reports commonly describe about four to eight hours, but sedation or sleep effects can outlast the useful phase.
• Half-life: Published estimates are roughly six to nine hours in healthy adults, with marked prolongation in renal impairment.
• Accumulation/steady state: Repeated dosing can accumulate over roughly one to two days; substantially longer if renal clearance is reduced.
• Near-complete elimination: Approximately 30–45 hours in healthy renal function using five half-lives, potentially much longer in kidney disease.
• Metabolism/elimination: Limited metabolism and predominantly renal elimination.

Healthy-volunteer Phase I pharmacokinetics · Oral and intravenous PK record

Evidence and Experiences

Clinical studies are old, heterogeneous, and weighted toward dementia or neurologic impairment. Modern work on the S-enantiomer provides safety and PK data, not proof that racemic gray-market oxiracetam enhances healthy cognition.

Forum reports vividly show individual variability: some call it mild, clean stimulation useful for coding or accounting; others feel relaxation, music enhancement, fatigue, irritability, or fog. Several say the difference appears only when they actually do mathematics or learning, while choline helps some and makes others worse. Mixed task, stimulation, and sedation reports

Safety, Interactions, and Monitoring

Reported effects include headache, nausea, dizziness, fatigue, agitation, irritability, insomnia, low mood, and impaired concentration. Stop for seizure, mania, suicidality, hallucinations, severe rash, fainting, persistent vomiting, or major neurologic change.

Use caution with other glutamatergic agents, cholinergics, stimulants, sedatives, seizure medicines, and complex psychiatric regimens. Kidney disease, pregnancy/breastfeeding, minors, bipolar disorder, psychosis, and seizure history require medical review. Dependence is not expected; tolerance reports are inconsistent and no evidence-based cycle exists. Product-quality testing should verify identity, assay, and contaminants; track sleep, headache, mood, task accuracy, delayed recall, pulse/BP, and next-day function.

Bottom Line

Oxiracetam has believable kinetics and a recognizable “clean analytical work” reputation, but neither guarantees healthy enhancement. The useful test is whether difficult work becomes measurably easier—not whether the capsule creates a stimulant sensation.

Spoiler: 24.4.4 Pramiracetam — Long, Narrow Focus Without Reliable Motivation

24.4.4 Pramiracetam — Long, Narrow Focus Without Reliable Motivation

What it is: Pramiracetam is N-[2-(diisopropylamino)ethyl]-2-oxo-1-pyrrolidineacetamide, commonly formulated as the sulfate salt. It is a more potent-by-mass investigational racetam, but potency by mass is not the same as stronger evidence or better cognition.

What it may feel like: Positive reports describe “blinders” coming down: one textbook, spreadsheet, or coding problem occupies the foreground and distractions lose their pull. The same narrowing can feel emotionally dry, antisocial, rigid, or joyless. Some users report clean memory and endurance; others get headache, fatigue, irritability, anxiety, insomnia, or nothing.

The simplest description: Pramiracetam is reputed to make the chosen lane narrower and easier to stay inside. It does not reliably choose the lane, create motivation, or ensure that the work is correct.

How It Works

No single human cognitive target is confirmed. Animal work suggests enhancement of high-affinity choline uptake in the hippocampus and downstream effects on acetylcholine-dependent memory processes; other membrane and signaling actions remain possible. This is not equivalent to directly releasing acetylcholine or proving that extra choline is required.

The compound is orally active and reaches the CNS, but modern brain-exposure data are limited. A substantial fraction is cleared renally, so kidney function and formulation matter.

Dose and How It Was Studied

A healthy-volunteer study tested single fasting doses of 400, 800, 1,200, and 1,600 mg; older clinical regimens commonly used hundreds of milligrams per administration. These figures document experiments, not a healthy-use recommendation.

Pramiracetam is often supplied as a sulfate and has formulation-dependent water solubility. Its intensely unpleasant powder and uncertain mucosal safety are reasons to avoid improvised sublingual use. A verified oral formulation may be taken with food for comfort; fat is not a substitute for validated manufacturing.

Timing and Pharmacokinetics

• Subjective onset: Often reported at one to two hours, though reliable human phenomenology is sparse.
• Pharmacologic onset / Tmax: Peak plasma concentration occurred about two to three hours after fasting oral doses.
• Absorption/bioavailability: Orally absorbed; accessible absolute-bioavailability data are limited.
• Full practical effect: Usually described once sustained task engagement is underway, not as an immediate launch.
• Subjective duration: Reports often place useful effects around five to eight hours, with sleep disruption sometimes lasting longer.
• Half-life: Human elimination half-life was approximately 4.5–6.5 hours.
• Accumulation/steady state: Repeated dosing could approach steady state within roughly one to two days; exact cognitive accumulation is unknown.
• Near-complete elimination: About one to one-and-a-half days after a single dose using five half-lives, longer with impaired renal function.
• Metabolism/elimination: Both renal and nonrenal clearance occur; complete public metabolite mapping is limited.

Healthy-volunteer oral pharmacokinetics

Evidence and Experiences

Human trials are small and old, involving healthy volunteers for tolerance/PK or selected impaired populations for efficacy. They do not establish a reliable study drug for healthy adolescents or college students.

Forum descriptions converge somewhat on narrow, emotionally neutral concentration and easier sustained reading, but negative accounts of flattening, irritability, headache, and no effect are substantial. Because “tunnel focus” can increase time spent on the wrong task, objective accuracy and task selection matter as much as persistence. These anecdotes cannot establish incidence or purity.

Safety, Interactions, and Monitoring

Headache, nausea, GI upset, fatigue, agitation, anxiety, insomnia, emotional blunting, and cognitive worsening are reported. Stop for mania, suicidality, hallucination, seizure, severe rash, chest symptoms, fainting, or persistent insomnia.

Use caution with other cholinergics, AMPA/glutamate-active compounds, stimulants, sedatives, anticoagulants, and psychiatric drugs. Kidney disease, pregnancy/breastfeeding, minors, bipolar disorder, psychosis, or seizure history require medical review. Dependence is not established; tolerance and cycling rules remain anecdotal. Product identity is a major risk: require assay and contaminant testing. Track work accuracy, flexibility, mood, social function, sleep, headache, and next-day performance.

Bottom Line

Pramiracetam’s useful mental image is narrow, durable task focus—not intelligence in a capsule. Human kinetics are clearer than the enhancement evidence, and emotional rigidity or fixation can turn the signature effect into the main drawback.

Spoiler: 24.4.5 Phenylpiracetam / Fonturacetam — Racetam-Like Cognition With Noticeable Physical Drive

24.4.5 Phenylpiracetam / Fonturacetam — Racetam-Like Cognition With Noticeable Physical Drive

What it is: Phenylpiracetam—also called fonturacetam, carphedon, or phenotropil—is piracetam with a phenyl group. Commercial material is usually racemic, while the R- and S-enantiomers do not necessarily share the same pharmacology.

What it may feel like: Responders often describe a cold morning becoming easier: movement takes less negotiation, fatigue feels farther away, vision seems more vivid, and work or exercise runs with calm physical momentum. It is usually much milder than amphetamine. Others feel only body stimulation, anxiety, vasoconstriction, irritability, insomnia, a later crash, or nothing; the noticeable “launch” often fades rapidly with repeated use.

The simplest description: Phenylpiracetam is the racetam most likely to feel like extra physical and mental traction, but the stimulating sensation is not proof of better memory.

How It Works

Mechanistic claims include racetam-like glutamatergic/cholinergic modulation plus enantiomer-dependent effects involving monoamine transporters and nicotinic signaling. Much of this evidence is preclinical or regional. Activity still matters: it may make movement or focused work easier to sustain, but it cannot select a useful goal.

It is orally active and brain penetrant. Public English-language human PK is surprisingly thin, and frequently repeated bioavailability and elimination numbers trace to regional summaries rather than transparent modern studies.

Dose and How It Was Studied

Regional medical and experimental reports commonly used low hundreds of milligrams, sometimes in courses. These are not a self-use recommendation, and escalating toward a stimulant feeling increases uncertainty and adverse effects. Phenylpiracetam is prohibited in sport by the World Anti-Doping Agency as a stimulant.

Its aqueous solubility is limited. Only a regulated finished oral product defines a studied preparation; dissolving unverified powder in water, oil, or under the tongue does not validate absorption or identity. Food may alter the speed or comfort of absorption, but a reliable food-effect study is not available.

Timing and Pharmacokinetics

• Subjective onset: Commonly reported around 30–60 minutes.
• Pharmacologic onset / Tmax: A defensible modern human Tmax is not publicly established; do not convert anecdotes into PK.
• Absorption/bioavailability: Orally active, but the often-repeated “nearly 100%” figure is not supported by accessible independent human data.
• Full practical effect: Reports usually place the clearest drive and endurance in the first one to three hours.
• Subjective duration: Commonly three to six hours, with insomnia or physical activation lasting longer in sensitive users.
• Half-life: Often quoted as 3–5 hours, but transparent primary human PK is lacking; treat it as provisional.
• Accumulation/steady state: Cannot be calculated confidently from public data. The felt stimulant component often diminishes within days.
• Near-complete elimination: The common five-half-life estimate would be roughly 15–25 hours, but this inherits the uncertain half-life.
• Metabolism/elimination: Regional summaries describe substantial unchanged urinary and biliary/sweat elimination; independent human mass-balance evidence is limited.

Evidence and Experiences

Clinical literature is largely Russian or Eastern European, often in neurologically impaired populations and difficult to generalize. There is no robust modern evidence that it improves healthy-person IQ, and stimulant-like effects are easier to perceive than memory effects.

Forum reports repeatedly describe mild wakefulness, cold tolerance, physical stamina, smoother work, verbal fluency, or a “top of my game” day. Others describe pure body stimulation without better thinking. Rapid tolerance to the energizing sensation is a dominant report, although whether cognitive effects share that tolerance is unknown. Subtle productivity account · Stimulation and tolerance discussion

Safety, Interactions, and Monitoring

Reported harms include anxiety, agitation, insomnia, headache, increased pulse/BP, vasoconstriction, appetite reduction, irritability, dysphoria, and compulsive redosing. Stop for chest pain, fainting, severe hypertension, mania, hallucination, suicidality, seizure, or prolonged insomnia.

Avoid combining casually with caffeine, amphetamines, methylphenidate, bupropion, MAO-active drugs, decongestants, or other stimulants. Bipolar disorder, psychosis, cardiovascular disease, pregnancy/breastfeeding, minors, and competitive drug-tested sport are major cautions. Dependence is not well characterized; stimulant-like reinforcement and fast tolerance make cycling anecdotes unreliable as a safety system. Track pulse/BP, sleep, anxiety, appetite, objective work, and next-day fatigue, and require identity, assay, enantiomeric composition, and contaminant testing.

Bottom Line

Phenylpiracetam is best pictured as added traction against fatigue and cold, not an amphetamine replacement or proven intelligence enhancer. Its physical drive is vivid, its healthy-cognition evidence is weak, and the very effect users chase is the one most often reported to fade.

Spoiler: 24.4.6 Coluracetam / MKC-231 / BCI-540 — The “HDR Vision” Racetam With Missing Public PK

24.4.6 Coluracetam / MKC-231 / BCI-540 — The “HDR Vision” Racetam With Missing Public PK

What it is: Coluracetam is a tricyclic substituted pyrrolidone developed first as MKC-231 and later as BCI-540. It entered clinical development for depression with anxiety but was never established as a cognitive enhancer.

What it may feel like: The signature anecdote is that the room looks as if someone raised color saturation: reds and greens appear richer, music becomes more absorbing, mood brightens, and focus feels calm. Other users feel only headache, nausea, an unpleasant body load, low mood, or nothing. Persistent visual change has also been reported and should be treated as a warning, not proof of optic-nerve “repair.”

The simplest description: Coluracetam is famous for making perception feel more vivid in some users, but the clinical and pharmacokinetic record is much less vivid than the anecdotes.

How It Works

Preclinical work suggests enhancement of high-affinity choline uptake, the transport step neurons use to acquire choline for acetylcholine synthesis. That is not the same as directly releasing acetylcholine, and it does not prove that adding alpha-GPC will improve the result. Animal effects on memory and mood do not establish the human mechanism.

It is practically insoluble in water and is soluble in laboratory organic solvents; this is a laboratory fact, not permission to swallow DMSO or other solvents. Human BBB exposure occurred sufficiently for clinical development to be plausible, but public quantitative CNS-selectivity data are weak.

Dose and How It Was Studied

A registered depression/anxiety study evaluated 80 mg once daily or 80 mg three times daily. That protocol is not a nootropic recommendation, and the trial population was clinically depressed rather than healthy. No safe consumer route or dose is established.

Because it is poorly water soluble, only a validated manufactured formulation defines interpretable exposure. Taking research powder with fat, under the tongue, or in a homemade solvent has no proven bioavailability advantage and adds mucosal/product uncertainty.

Timing and Pharmacokinetics

• Subjective onset: Forum reports often say 20–60 minutes, but this is anecdotal.
• Pharmacologic onset / Tmax: Public human Tmax is not adequately established.
• Absorption/bioavailability: Humans received it orally in trials, but usable absolute-bioavailability data are not public.
• Full practical effect: Anecdotes usually place visual, mood, or focus changes in the first few hours.
• Subjective duration: Commonly reported around three to five hours, with occasional claims of much longer visual change.
• Half-life: A reliable public human value is unavailable.
• Accumulation/steady state: Unknown.
• Near-complete elimination: Cannot be calculated responsibly.
• Metabolism/elimination: Public human pathways are insufficiently characterized.

Registered Phase II depression/anxiety study

Evidence and Experiences

Clinical evidence is limited to development in major depression with concomitant anxiety; public claims of a positive subgroup signal do not establish healthy enhancement. Preclinical memory findings remain preclinical.

Forum reports split sharply between “HDR” colors, music enhancement, bright mood, calm focus, and total nonresponse. Some describe a narrow dose window in which more becomes dysphoric or physically unpleasant. A report of months-long color change with light sensitivity is uncontrolled, but it is exactly the kind of outlier that argues against treating visual alteration as automatically beneficial. Mixed visual and headache reports · Persistent-visual-change report

Safety, Interactions, and Monitoring

Human incidence is not adequately known. Headache, nausea, anxiety, low mood, body discomfort, insomnia, visual sensitivity, and cognitive worsening require attention. Stop and seek evaluation for persistent visual change, severe headache, seizure, mania, suicidality, hallucination, fainting, chest symptoms, or severe rash.

Use caution with cholinergics, acetylcholinesterase inhibitors, nicotine, serotonergic or psychiatric drugs, psychedelics, and other research chemicals. Dependence and tolerance are unquantified; reports of a spectacular first response that never returns do not justify escalation. Product-quality testing must confirm identity, assay, impurities, solvents, and contaminants. Track vision/light sensitivity, mood, sleep, headache, task accuracy, and next-day function.

Bottom Line

Coluracetam has one of the clearest anecdotal signatures in the family and one of the weakest practical PK datasets. “Colors look richer” is a report, not an efficacy endpoint, and persistent perception change belongs in the risk column.

Spoiler: 24.4.7 Fasoracetam / NS-105 / NFC-1 — Calm Focus in Some Users, Genotype-Selected Clinical Evidence in Others

24.4.7 Fasoracetam / NS-105 / NFC-1 — Calm Focus in Some Users, Genotype-Selected Clinical Evidence in Others

What it is: Fasoracetam is a water-soluble pyrrolidone developed as NS-105 and later NFC-1. Unlike the classic racetams, its main research story centers on metabotropic glutamate receptors and downstream GABA/cholinergic adaptation.

What it may feel like: A responder may notice that the internal argument about starting work becomes quieter: anxiety drops, speech flows, and focus feels relaxed instead of chemically driven. Others experience early restlessness followed by calm, sedation, sexual side effects, fog, irritability, or nothing. It is not a proven phenibut-withdrawal antidote.

The simplest description: Fasoracetam may turn down noisy background interference while leaving you awake enough to work, but the effect is variable and the best human signal came from a selected genetic subgroup.

How It Works

Fasoracetam modulates group I and group II/III metabotropic glutamate receptors (mGluRs) rather than acting as a classic stimulant. Preclinical work also suggests increased high-affinity choline uptake and chronic upregulation of GABA-B-receptor function. The popular claim that a few doses “reset” phenibut or baclofen tolerance is not established in humans.

It is orally absorbed, highly bioavailable in human development summaries, and centrally active. Effects are not purely central: GI, sexual, mood, and sleep changes can dominate the real experience.

Dose and How It Was Studied

An adolescent ADHD study performed single-dose PK at 50–800 mg, then titrated selected participants up to 400 mg twice daily over four weeks. The study involved 30 adolescents with mGluR-network variants and used an open-label/single-blind design; it is not a general healthy-user dose guide.

Fasoracetam is water soluble and a trial capsule can be taken with water. Fasting is not proven superior, and sublingual loose powder has no validated advantage over the studied oral formulation. Food can be used for stomach comfort unless a protocol specifies otherwise.

Timing and Pharmacokinetics

• Subjective onset: Reports range from 30 minutes to two hours.
• Pharmacologic onset / Tmax: In the adolescent PK study, mean Tmax was roughly 1.3–1.9 hours across 50–800 mg.
• Absorption/bioavailability: Prior human summaries report approximately 79–97% oral bioavailability.
• Full practical effect: Acute calm/focus may appear the same day; proposed receptor adaptation would require repeated exposure and is not validated as a consumer outcome.
• Subjective duration: Commonly described as four to eight hours, with delayed calm sometimes outlasting the obvious phase.
• Half-life: Prior human summaries place it around 4–6.5 hours.
• Accumulation/steady state: Approximate pharmacokinetic steady state should occur within one to two days, while receptor adaptation may follow a different schedule.
• Near-complete elimination: Roughly 20–33 hours using five half-lives.
• Metabolism/elimination: Reported to be eliminated largely in urine, much of it unchanged.

Adolescent genotype-selected ADHD study

Evidence and Experiences

The most discussed human study found symptom improvement in a small, genotype-selected adolescent ADHD sample, without a conventional parallel double-blind design. Earlier dementia development did not establish broad efficacy. This is a precision-medicine research signal, not evidence that any anxious or inattentive student will respond.

Forum reports include calm focus, less social anxiety, easier speech, delayed relaxation, stimulation, withdrawal-like symptoms after long continuous use, and total nonresponse. Reports that it rescues phenibut withdrawal are especially confounded and medically risky. Mixed stimulation and relaxed-focus reports · Long-term use and cessation symptoms

Safety, Interactions, and Monitoring

Reported effects include headache, fatigue, nausea, anxiety, sedation, insomnia, irritability, libido/sexual changes, and mood alteration. Stop for seizure, mania, suicidality, hallucination, severe rash, fainting, chest symptoms, or severe/prolonged withdrawal-like symptoms.

Do not treat it as a home detox tool. Phenibut, baclofen, alcohol, benzodiazepines, gabapentinoids, stimulants, glutamatergic agents, and psychiatric drugs require professional review. Dependence is unproven but long-term users report tolerance and difficult cessation; no evidence-based cycle exists. Product-quality testing should confirm hydrate/form, identity, assay, solvents, and contaminants. Track anxiety, sleep, pulse/BP, sexual effects, cognition, and next-day function.

Bottom Line

Fasoracetam has real human PK and an intriguing selected-ADHD signal, but its internet identity as a universal calm-focus drug or GABA-B reset button runs ahead of the evidence. The practical response is highly individual, and withdrawal-treatment experiments are not casual nootropic use.

Spoiler: 24.4.8 Nefiracetam / DM-9384 — Smooth Mood-and-Memory Reports With a Serious Toxicology Footnote

24.4.8 Nefiracetam / DM-9384 — Smooth Mood-and-Memory Reports With a Serious Toxicology Footnote

What it is: Nefiracetam is N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide, an orally active racetam studied in healthy volunteers and neurologically impaired patients.

What it may feel like: Positive reports describe fog lifting without a hard stimulant edge: anxiety quiets, recall and verbal flow improve, and mood feels stable for several hours. Others report nausea, headache, sedation, low mood, or a depressive after-effect after stopping. Animal renal and testicular toxicity makes “it felt smooth” an inadequate safety argument.

The simplest description: Nefiracetam may feel like cognition becoming usable again rather than accelerated, but its attractive subjective profile sits beside unresolved long-term safety.

How It Works

Nefiracetam has complex preclinical effects involving cholinergic signaling, calcium channels, NMDA-related glutamate signaling, GABA-A receptors, and protein-kinase pathways. No single mechanism has been proven to explain human cognition. Animal studies suggest repeated exposure may matter more than one acute dose.

It is only modestly water soluble and undergoes substantial metabolism. Parent drug and metabolites reach systemic circulation, with metabolite half-lives longer than the parent.

Dose and How It Was Studied

Healthy-volunteer PK tested 10–200 mg single doses and 200 mg three times daily for seven days. Those high research exposures are not a recommendation, especially given species-dependent toxicology and the absence of an approved healthy-cognition indication.

Food delayed absorption without materially changing total pharmacokinetics. A verified oral formulation may therefore be taken with or without food depending on timing and stomach comfort. Laboratory ethanol/DMSO solubility does not justify homemade solvent or sublingual preparations.

Timing and Pharmacokinetics

• Subjective onset: Forum users often report 30–90 minutes, but repeated-use effects may be less immediate.
• Pharmacologic onset / Tmax: Parent drug peaks within two hours; one study measured about 1.6 hours after 200 mg.
• Absorption/bioavailability: Orally absorbed with linear exposure from 10–200 mg; absolute bioavailability is not clearly established.
• Full practical effect: Acute mood/fog changes may appear the same day, while memory claims are often tied to repeated use.
• Subjective duration: Commonly described as four to six hours.
• Half-life: Parent nefiracetam about 3–5 hours; measured metabolites about 7.8–21.9 hours.
• Accumulation/steady state: Parent did not show clinically significant accumulation in the seven-day study; metabolite profiles reached steady state by about day seven.
• Near-complete elimination: Parent roughly 15–25 hours by five half-lives, but some metabolites may require approximately two to five days.
• Metabolism/elimination: Extensively metabolized; less than 10% recovered unchanged in urine, with urinary metabolites accounting for a substantial fraction.

Single- and multiple-dose human PK

Evidence and Experiences

Human evidence includes PK/safety work and older trials in cerebrovascular or cognitive impairment, not persuasive healthy-person enhancement trials. Animal renal and testicular toxicity appears species/metabolite dependent, but that does not prove long-term human safety.

Forum reports include calm stimulation, reduced fog and anxiety, verbal fluency, and stable mood; others describe nausea, melancholy, or depression after cessation. These accounts are sparse and products are unregulated. Mood, fog, and cessation reports · Subtle stimulation and recall reports

Safety, Interactions, and Monitoring

Headache, nausea, GI upset, fatigue, sedation, insomnia, mood change, and cognitive worsening are plausible. Stop for severe depression/suicidality, seizure, mania, hallucination, rash, fainting, persistent vomiting, testicular pain/swelling, urinary change, or flank pain.

Use caution with cholinergics, glutamatergic/GABAergic drugs, sedatives, stimulants, and psychiatric medication. Kidney or reproductive disease, pregnancy/breastfeeding, minors, bipolar disorder, psychosis, and seizure history are major cautions. Dependence is unestablished; cessation-related low mood and tolerance reports mean cycling is not a proven safety solution. Product-quality testing should confirm identity/assay and contaminants. Long-term experimentation would require medical renal, hepatic, and reproductive monitoring—not merely a mood diary.

Bottom Line

Nefiracetam has clearer human kinetics than most experimental racetams and a relatable calm, fog-clearing reputation. The unresolved toxicology and metabolite duration are precisely why it should not be reduced to “smooth focus for five hours.”

24.5 Racetam-Like Compounds​

Noopept is placed beside the racetams because it was developed in the same conceptual tradition and is discussed by the same users. It is not structurally a racetam, and calling it “the most potent racetam” confuses dose mass, chemical identity, and demonstrated efficacy.

Spoiler: 24.5.1 Noopept / Omberacetam / GVS-111 — Cold, Task-Locked Clarity in Some Users and Brain Fog in Others

24.5.1 Noopept / Omberacetam / GVS-111 — Cold, Task-Locked Clarity in Some Users and Brain Fog in Others

What it is: Noopept—N-phenylacetyl-L-prolylglycine ethyl ester, also called omberacetam or GVS-111—is a synthetic Pro-Gly-related molecule, not structurally a racetam. It is used medicinally in Russia for selected cognitive complaints but is unapproved as a drug or supplement in the United States.

What it may feel like: A responder may sit down and simply stop negotiating with the task: writing becomes easy to continue, irrelevant emotional noise recedes, and attention feels “cold” and logical rather than stimulated. Some describe cleaner recall, brighter colors, less anxiety, or greater mental stamina. Others become irritable, emotionally numb, forgetful, foggy, exhausted, anxious, dissociated, headachy, or unable to sleep—and many feel nothing.

The simplest description: Noopept can feel as if the brain has narrowed onto what objectively needs doing, but that same narrowing may become emotional flattening or poor short-term memory.

How It Works

Preclinical research proposes glutamatergic modulation, antioxidant and neuroprotective signaling, and changes in BDNF/NGF expression. It is also described as a precursor to cycloprolylglycine-related metabolites. These animal mechanisms do not establish that an acute human dose “raises BDNF” enough to improve healthy cognition.

The parent compound and metabolites are intended to act centrally, but dependable quantitative human BBB, target-engagement, and parent-versus-metabolite kinetics remain sparse.

Dose and How It Was Studied

The Russian tablet contains 10 mg, and regional labeling commonly uses 10 mg twice daily after meals, sometimes increasing under medical direction; a comparative impaired-patient study also used low-milligram repeated dosing. This is regional clinical practice, not a recommendation for healthy students. Internet sublingual and intranasal regimens are not the studied oral tablet.

Consumer solubility is poorly summarized and formulation matters. The most interpretable route is a verified finished oral product taken as labeled, commonly after food for tolerability. Fasting is not proven superior, while improvised sublingual or nasal powder changes exposure and mucosal risk without supplying validated bioavailability.

Timing and Pharmacokinetics

• Subjective onset: Oral reports commonly place it around 30–90 minutes; sublingual claims are faster but uncontrolled.
• Pharmacologic onset / Tmax: A dependable modern human parent-drug Tmax is not publicly established.
• Absorption/bioavailability: It is orally active in regional clinical use, but robust absolute human bioavailability is unavailable.
• Full practical effect: Acute task focus may appear the same day; regional courses and clinical studies assess cognition over weeks, not minutes.
• Subjective duration: Commonly reported as three to six hours, with mood, sleep, or fog sometimes lasting into the next day.
• Half-life: Widely repeated minute-scale figures come mainly from rodents and should not be presented as a human half-life.
• Accumulation/steady state: Cannot be calculated from reliable human parent/metabolite data; downstream adaptation may follow a different schedule.
• Near-complete elimination: Unknown in humans.
• Metabolism/elimination: Rapid conversion to peptide-related metabolites is proposed, but a complete practical human mass-balance map is unavailable.

Regional product information · Market-surveillance evidence for mislabeling risk

Evidence and Experiences

Human evidence is limited, regional, and concentrated in people with mild cognitive impairment after vascular or traumatic brain disease. It does not establish a reliable enhancement effect in healthy young adults. Much of the molecular enthusiasm is preclinical.

Forum reports are intensely dose- and person-dependent. Positive accounts describe logic-driven productivity, easier writing, reduced anxiety, focus, and stamina; negative accounts describe irritability, emotional numbness, poor recall, tinnitus, panic, derealization, or heavy fatigue. Several users say sleep quality determines whether it feels useful or awful. These stories make the possible experience vivid but cannot establish purity or incidence. Broad positive/negative discussion · Severe fog and dissociation report

Safety, Interactions, and Monitoring

Reported effects include headache, irritability, anxiety, insomnia, fatigue, nausea, blood-pressure change, emotional blunting, memory worsening, tinnitus, and dissociation. Stop and seek care for allergic throat swelling, seizure, mania, suicidality, hallucination, severe/persistent derealization, chest symptoms, fainting, or prolonged insomnia.

Use caution with racetams/AMPA modulators, cholinergics, stimulants, serotonergic or other psychiatric drugs, and complex stacks. Pregnancy/breastfeeding, minors, bipolar disorder, psychosis, seizure history, and serious liver/kidney disease lack a safe self-use basis. Dependence is not established; tolerance, rebound fog, and withdrawal-like anecdotes exist, while popular six-to-eight-week cycles are not proven safety protocols. Product-quality testing should confirm omberacetam identity, assay, impurities, residual solvents, and contaminants. Track sleep, irritability, mood, immediate and delayed recall, task accuracy, BP/pulse, and next-day function.

Bottom Line

Noopept is compact by dose but not simple by effect. Its best-case image is cold, effortless task focus; its worst-case image is irritability, emotional disconnection, and memory getting worse. Human PK is too incomplete to pretend the rodent half-life explains either response.

24.6 Racetam Monitoring​

Track one verified compound at a time, formulation, clock time, food, sleep, headache, mood, pulse, blood pressure when relevant, task-entry latency, error rate, delayed recall, verbal mistakes, and next-day function. A useful profile must improve the target behavior without quietly worsening sleep, emotional control, or objective accuracy.

---

@Volpa #Volpamogs​

 

[enchanted_elixir]

@youcouldbetheone @Deathninja328 @mangotimer @psltristan1 @Leo @Jgns @ghoulmania